Published in Women's Health Weekly, August 14th, 2008
"Patients were randomly assigned to i.v. ibandronate 6 mg every 3-4 weeks for <= 6 months, infusion over 15 min (n = 102) or 60 min (n = 28). The primary end point was the percentage of patients with increased serum creatinine of >= 44.2 mu mol/l. Blood chemistry was assessed at each visit. Two per cent [2/101; 95% confidence interval (CI) 0.2-7.0] of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly